Lymphoma - B cell neoplasms
B cell disorders
Reviewer: Nikhil Sangle, M.D., University of Utah and ARUP Laboratories (see Reviewers page)
Revised: 2 February 2011, last major update February 2011
Copyright: (c) 2001-2011, PathologyOutlines.com, Inc.
● Rituximab is an anti-CD20 antibody widely used to treat lymphoma
● Loss of CD20 expression is common at relapse of aggressive B cell lymphoma treated with rituximab (Br J Haematol 2002;119:412)
● Post-rituximab, tumors may show loss of CD20 expression with proliferation of plasmacytoid cells, transformation to classic Hodgkin's lymphoma or transformation to an anaplastic large cell lymphoma-like undifferentiated lymphoma (Cancer Sci 2009;100:54)
● Recurrent CD20 negative cases are often clonally related to pre-rituximab tumor (Leuk Lymphoma 2002;43:2335)
● Bone marrow specimens may contain T cell aggregates that suggest relapse, so ordering immunostains is important (Am J Clin Path 1999;112:844)
● CD79a and Pax-5 should be used as the first-line B lineage-specific markers to detect CD20 negative mature B-cell lymphomas; if negative, OCT.2 or BOB.1 may be useful (Am J Clin Path 2006;126:534)
● CD20 antigen may reappear after relapse of CD20-negative tumor (Haematologica 2007;92:e1)
Reappearance of CD20 antigen after relapse of CD20 negative tumor
End of Lymphoma - B cell neoplasms > B cell disorders > Post-rituximab
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).